Pharmacovigilance Market SWOT Analysis by 2031
Pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. Pharmacovigilance plays a significant role in pharmaceutical and biotechnological sectors in designing of drugs and their interactions. The pharmacovigilance involves collecting information from healthcare providers and patients to know about the hazards associated with medications.
Increasing cases of adverse drug reactions and increasing consumption of drugs across the globe are expected to fuel the growth of the pharmacovigilance market during the forecast period. Moreover, shift in outsourcing of various activities among pharmaceutical and life science sector is anticipated to offer significant growth opportunities in the market.
The "Global Pharmacovigilance Market Analysis to 2031" is a specialized and in-depth study of the healthcare IT industry with a focus on the global market trend. The report aims to provide an overview of global market with detailed market segmentation by clinical trial phase, service provider, type of method, end user and geography. The global market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading pharmacovigilance market players and offers key trends and opportunities in the market.
The global pharmacovigilance market is segmented on the basis of clinical trial phase, service provider, type of method, and end user. Based on clinical trial phase, the market is classified as, Pre-Clinical, Phase I, Phase II, Phase III, and Phase IV. Similarly, on the basis of service type, the market is categorized as, in-house and contract outsourcing. The pharmacovigilance market is segmented based on type of method such as, spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, and EHR mining. On the basis of end user, the market is classified as, hospitals, research organizations, and industrial.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global pharmacovigilance market based clinical trial phase, service provider, type of method, and end user. It also provides market size and forecast till 2031 for overall market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The pharmacovigilance market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 counties globally along with current trend and opportunities prevailing in the region.
North America is expected to contribute to the largest share in the pharmacovigilance market in the coming years, owing to the presence of major market players in the region along with the initiatives to reduce the healthcare expenditure as well as sophisticated healthcare infrastructure. Asia Pacific is anticipated to witness significant growth in the market during the forecast period, due to rising adoption of IT in the field of healthcare top offer better services to the patients.
The report analyzes factors affecting pharmacovigilance market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Pharmacovigilance market in these regions.
The report also includes the profiles of key pharmacovigilance companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years. Some of the key players operating in the pharmacovigilance market include, Accenture, Bristol-Myers Squibb Company, Linical Accelovance, Cognizant, Covance Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., ICON plc, Capgemini (IGATE Corporation), and Novartis AG among others.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1. Pharmacovigilance Market- By Clinical Trial Phase
1.3.2. Pharmacovigilance Market- By Service Provider
1.3.3. Pharmacovigilance Market- By Type of Method
1.3.4. Pharmacovigilance Market- By End User
1.3.5. Pharmacovigilance Market- By Region
1.3.5.1. By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. PHARMACOVIGILANCE MARKET LANDSCAPE
4.1. MARKET OVERVIEW
4.2. PEST ANALYSIS
4.2.1. North America - PEST Analysis
4.2.2. Europe - PEST Analysis
4.2.3. Asia Pacific - PEST Analysis
4.2.4. Middle East & Africa - PEST Analysis
4.2.5. South and Central America - PEST Analysis
5. PHARMACOVIGILANCE MARKET- KEY INDUSTRY DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. PHARMACOVIGILANCE MARKET- GLOBAL ANALYSIS
6.1. PHARMACOVIGILANCE MARKET - GLOBAL MARKET OVERVIEW
6.2. PHARMACOVIGILANCE MARKET - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/ MARKET SHARE OF KEY PLAYERS
7. PHARMACOVIGILANCE MARKET REVENUE AND FORECASTS TO 2028 - BY CLINICAL TRIAL PHASE
7.1. OVERVIEW
7.2. CLINICAL TRIAL PHASE MARKET FORECASTS AND ANALYSIS
7.3. PRE-CLINICAL MARKET
7.3.1. Overview
7.3.2. Pre-Clinical Market Forecast and Analysis (US$ Mn)
7.4. PHASE-I MARKET
7.4.1. Overview
7.4.2. Phase-I Market Forecast and Analysis (US$ Mn)
7.5. PHASE-II MARKET
7.5.1. Overview
7.5.2. Phase-II Market Forecast and Analysis (US$ Mn)
7.6. PHASE-III MARKET
7.6.1. Overview
7.6.2. Phase-III Market Forecast and Analysis (US$ Mn)
7.7. PHASE-IV MARKET
7.7.1. Overview
7.7.2. Phase-IV Market Forecast and Analysis (US$ Mn)
8. PHARMACOVIGILANCE MARKET REVENUE AND FORECASTS TO 2028 - BY SERVICE PROVIDER
8.1. OVERVIEW
8.2. SERVICE PROVIDER MARKET FORECASTS AND ANALYSIS
8.3. IN-HOUSE MARKET
8.3.1. Overview
8.3.2. In-House Market Forecast and Analysis (US$ Mn)
8.4. CONTRACT OUTSOURCING MARKET
8.4.1. Overview
8.4.2. Contract Outsourcing Market Forecast and Analysis (US$ Mn)
9. PHARMACOVIGILANCE MARKET REVENUE AND FORECASTS TO 2028 - BY TYPE OF METHOD
9.1. OVERVIEW
9.2. TYPE OF METHOD MARKET FORECASTS AND ANALYSIS
9.3. SPONTANEOUS REPORTING MARKET
9.3.1. Overview
9.3.2. Spontaneous Reporting Market Forecast and Analysis (US$ Mn)
9.4. INTENSIFIED ADR REPORTING MARKET
9.4.1. Overview
9.4.2. Intensified ADR Reporting Market Forecast and Analysis (US$ Mn)
9.5. TARGETED SPONTANEOUS REPORTING MARKET
9.5.1. Overview
9.5.2. Targeted Spontaneous Reporting Market Forecast and Analysis (US$ Mn)
9.6. COHORT EVENT MONITORING MARKET
9.6.1. Overview
9.6.2. Cohort Event Monitoring Market Forecast and Analysis (US$ Mn)
9.7. EHR MINING MARKET
9.7.1. Overview
9.7.2. EHR Mining Market Forecast and Analysis (US$ Mn)
10. PHARMACOVIGILANCE MARKET REVENUE AND FORECASTS TO 2028 - BY END USER
10.1. OVERVIEW
10.2. END USER MARKET FORECASTS AND ANALYSIS
10.3. HOSPITALS MARKET
10.3.1. Overview
10.3.2. Hospitals Market Forecast and Analysis (US$ Mn)
10.4. RESEARCH ORGANIZATIONS MARKET
10.4.1. Overview
10.4.2. Research Organizations Market Forecast and Analysis (US$ Mn)
10.5. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET
10.5.1. Overview
10.5.2. Pharmaceutical and Biotechnology Companies Market Forecast and Analysis (US$ Mn)
11. PHARMACOVIGILANCE MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA PHARMACOVIGILANCE MARKET
11.1.1. North America Pharmacovigilance Market Forecasts and Analysis (US$ Mn)
11.1.2. North America Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.1.3. North America Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.1.4. North America Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.1.5. North America Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.1.6. North America Pharmacovigilance Market Forecasts and Analysis - By Country
11.1.7. US Market Overview
11.1.7.1. US Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.1.7.2. US Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.1.7.3. US Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.1.7.4. US Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.1.8. Canada Market Overview
11.1.8.1. Canada Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.1.8.2. Canada Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.1.8.3. Canada Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.1.8.4. Canada Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.1.9. Mexico Market Overview
11.1.9.1. Mexico Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.1.9.2. Mexico Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.1.9.3. Mexico Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.1.9.4. Mexico Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.2. EUROPE PHARMACOVIGILANCE MARKET
11.2.1. Europe Pharmacovigilance Market Forecasts and Analysis (US$ Mn)
11.2.2. Europe Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.2.3. Europe Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.2.4. Europe Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.2.5. Europe Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.2.6. Europe Pharmacovigilance Market Forecasts and Analysis - By Country
11.2.7. UK Market Overview
11.2.7.1. UK Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.2.7.2. UK Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.2.7.3. UK Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.2.7.4. UK Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.2.8. Germany Market Overview
11.2.8.1. Germany Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.2.8.2. Germany Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.2.8.3. Germany Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.2.8.4. Germany Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.2.9. France Market Overview
11.2.9.1. France Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.2.9.2. France Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.2.9.3. France Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.2.9.4. France Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.2.10. Spain Market Overview
11.2.10.1. Spain Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.2.10.2. Spain Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.2.10.3. Spain Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.2.10.4. Spain Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.2.11. Italy Market Overview
11.2.11.1. Italy Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.2.11.2. Italy Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.2.11.3. Italy Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.2.11.4. Italy Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.3. ASIA PACIFIC PHARMACOVIGILANCE MARKET
11.3.1. Asia Pacific Pharmacovigilance Market Forecasts and Analysis (US$ Mn)
11.3.2. Asia Pacific Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.3.3. Asia Pacific Pharmacovigilance Market Forecasts and Analysis - By Type (US$ Mn)
11.3.4. Asia Pacific Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.3.5. Asia Pacific Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.3.6. Asia Pacific Pharmacovigilance Market Forecasts and Analysis - By Country
11.3.7. Japan Market Overview
11.3.7.1. Japan Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.3.7.2. Japan Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.3.7.3. Japan Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.3.7.4. Japan Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.3.8. China Market Overview
11.3.8.1. China Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.3.8.2. China Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.3.8.3. China Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.3.8.4. China Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.3.9. India Market Overview
11.3.9.1. India Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.3.9.2. India Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.3.9.3. India Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.3.9.4. India Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.3.10. Australia Market Overview
11.3.10.1. Australia Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.3.10.2. Australia Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.3.10.3. Australia Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.3.10.4. Australia Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.3.11. South Korea Market Overview
11.3.11.1. South Korea Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.3.11.2. South Korea Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.3.11.3. South Korea Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.3.11.4. South Korea Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.4. MIDDLE EAST & AFRICA (MEA) PHARMACOVIGILANCE MARKET
11.4.1. Middle East & Africa (MEA) Pharmacovigilance Market Forecasts and Analysis (US$ Mn)
11.4.2. Middle East & Africa (MEA) Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.4.3. Middle East & Africa (MEA) Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.4.4. Middle East & Africa (MEA) Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.4.5. Middle East and Africa Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.4.6. Middle East & Africa (MEA) Pharmacovigilance Market Forecasts and Analysis - By Country
11.4.7. South Africa Market Overview
11.4.7.1. South Africa Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.4.7.2. South Africa Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.4.7.3. South Africa Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.4.7.4. South Africa Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.4.8. Saudi Arabia Market Overview
11.4.8.1. Saudi Arabia Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.4.8.2. Saudi Arabia Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.4.8.3. Saudi Arabia Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.4.8.4. Saudi Arabia Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.4.9. UAE Market Overview
11.4.9.1. UAE Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.4.9.2. UAE Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.4.9.3. UAE Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.4.9.4. UAE Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.5. SOUTH AND CENTRAL AMERICA PHARMACOVIGILANCE MARKET
11.5.1. South and Central America Pharmacovigilance Market Forecasts and Analysis (US$ Mn)
11.5.2. South and Central America Pharmacovigilance Market Forecasts and Analysis - By Product (US$ Mn)
11.5.3. South and Central America Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.5.4. South and Central America Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.5.5. South and Central America Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.5.6. South and Central America Pharmacovigilance Market Forecasts and Analysis - By Country
11.5.7. Brazil Market Overview
11.5.7.1. Brazil Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.5.7.2. Brazil Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.5.7.3. Brazil Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.5.7.4. Brazil Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.5.8. Argentina Market Overview
11.5.8.1. Argentina Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.5.8.2. Argentina Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.5.8.3. Argentina Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.5.8.4. Argentina Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
12. INDUSTRY LANDSCAPE
1.1. ORGANIC GROWTH STRATEGIES
1.1.1. New Product Launches
1.1.2. Marketing & Promotional Activities
1.2. INORGANIC GROWTH STRATEGIES
1.2.1. Partnerships, Collaborations, and Joint Ventures
1.2.2. Mergers & Acquisitions
13. PHARMACOVIGILANCE MARKET, KEY COMPANY PROFILES
13.1. ACCENTURE
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Financial Overview
13.1.4. Product Portfolio
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. BRISTOL-MYERS SQUIBB COMPANY
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Financial Overview
13.2.4. Product Portfolio
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. LINICAL ACCELOVANCE
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Financial Overview
13.3.4. Product Portfolio
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. COGNIZANT
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Financial Overview
13.4.4. Product Portfolio
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. COVANCE INC. (LABORATORY CORPORATION OF AMERICA HOLDINGS)
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Financial Overview
13.5.4. Product Portfolio
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. F. HOFFMANN-LA ROCHE LTD.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Financial Overview
13.6.4. Product Portfolio
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. GLAXOSMITHKLINE PLC.
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Financial Overview
13.7.4. Product Portfolio
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. ICON PLC
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Financial Overview
13.8.4. Product Portfolio
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. CAPGEMINI (IGATE CORPORATION)
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Financial Overview
13.9.4. Product Portfolio
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. NOVARTIS AG
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Financial Overview
13.10.4. Product Portfolio
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies
1. Accenture
2. Bristol-Myers Squibb Company
3. Linical Accelovance
4. Cognizant
5. Covance Inc.
6. F. Hoffmann-La Roche Ltd.
7. GlaxoSmithKline plc.
8. ICON plc
9. Capgemini (IGATE Corporation)
10. Novartis AG
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For